SCHEMBL24495261

SCHEMBL24495261

CN(C)CC1CN(c2ccc(Br)cc2)CCO1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.40
LRRK2 Q5S007 2/20 0.38
TDP1 Q9NUW8 1/20 0.37
TRPA1 O75762 5/20 0.36
AKR1C3 P42330 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 1/20 0.35
PDE10A Q9Y233 1/20 0.34
CHEK1 O14757 2/20 0.33
PIM1 P11309 2/20 0.33
PRKACA P17612 2/20 0.33
CLK2 P49760 2/20 0.33
GSK3A P49840 2/20 0.33
GSK3B P49841 2/20 0.33
CDK7 P50613 2/20 0.33
RPS6KA3 P51812 2/20 0.33
JAK3 P52333 2/20 0.33
PRKCQ Q04759 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16440191 0.87 GAA (0.43) SYKLRRK2TRPA1AKR1C3MEN1
SCHEMBL12236016 0.86 SYK (0.42) SYKLRRK2TDP1TRPA1MEN1
SCHEMBL2505100 0.86 SYK (0.42) SYKLRRK2TDP1TRPA1MEN1
SCHEMBL18436051 0.85 LMNA (0.43) SYKLRRK2CHEK1PIM1PRKACA
SCHEMBL23114522 0.84 TDP1 (0.40) SYKLRRK2TDP1TRPA1MEN1
SCHEMBL19012754 0.84 TDP1 (0.40) SYKLRRK2TDP1TRPA1MEN1
SCHEMBL23103287 0.83 DRD4 (0.40) SYKLRRK2TRPA1MEN1KMT2A
SCHEMBL24859545 0.83 DRD4 (0.40) SYKLRRK2TRPA1MEN1KMT2A
SCHEMBL23103282 0.83 DRD4 (0.40) SYKLRRK2TRPA1MEN1KMT2A
SCHEMBL23107110 0.83 ALDH1A1 (0.46) SYKLRRK2TDP1TRPA1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018154-A1 NEW INDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2024-01-18 US disclosed
US-20240018154-A1 NEW INDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2024-01-18 US disclosed
EP-4255906-A1 NEW INDAZOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2023-10-11 EP disclosed
CN-116600806-A Indazole derivatives 豪夫迈·罗氏有限公司 2023-08-15 CN disclosed
WO-2022117487-A1 NEW INDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2022-06-09 WO disclosed
WO-2022117487-A1 NEW INDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2022-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018154-A1 NEW INDAZOLE DERIVATIVES CYP3A43, CYP3A4, CYP3A5 SYK 932/4885LRRK2 1566/4885TDP1 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.